Connor, Clark & Lunn Investment Management (CC&L)
PSTX

Connor, Clark & Lunn Investment Management (CC&L)’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-153,058
Closed -$1.47M – 1652
2024
Q4 		$1.47M Sell
153,058
-206,139
-57% -$1.08M 0.01% 817
2024
Q3 		$1.03M Buy
359,197
+138,510
+63% +$429K 0.01% 879
2024
Q2 		$644K Sell
220,687
-283,073
-56% -$774K ﹤0.01% 977
2024
Q1 		$1.61M Buy
503,760
+129,238
+35% +$431K 0.01% 733
2023
Q4 		$1.26M Buy
374,522
+31,665
+9% +$81.6K 0.01% 793
2023
Q3 		$816K Buy
342,857
+223,280
+187% +$468K ﹤0.01% 884
2023
Q2 		$210K Buy
+119,577
New +$305K ﹤0.01% 1182

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s PSTX Position: Q1 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 153,058 shares — an estimated $1.47M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PSTX in Q2 2023 and held it in 7 quarters. The position peaked at $1.61M in Q1 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 153,058 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $1.47M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Poseida Therapeutics, Inc. Common Stock in Q2 2023 and held it in 7 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Poseida Therapeutics, Inc. Common Stock position peaked at $1.61M in Q1 2024.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2025, filed 12 May 2025.